Proposed MolDX LCDs

When there are Proposed Local Coverage Determinations (LCDs) that are in the comment period, this webpage will provide a summary of comments received and Noridian's response. This information will remain on this webpage for at least six months.

Status Indicators

D = Proposed under development, not yet released for comment
C = Proposed MolDX LCD released for comment
E = Formal comment period has ended; comments now being considered
F = Final new/revised MolDX LCD has been issued for notice
A = Active policy: notice period complete and the policy is in effect

Send Proposed MolDX LCD Comments to:

Mail:
Noridian Medicare JF Part B
Attention: Proposed LCD Comments
PO Box 6781
Fargo, ND 58108-6781
Email: policydraft@noridian.com

 
Proposed LCD and Billing and Coding Article Title Release Date of Proposed LCD for Comment End Date for Comment Period Current Status Comments / Responses Date of Release for Notice Link to Final LCD

MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers

Billing and Coding: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers

 08/31/23 10/14/23 F View 08/08/24 View
MolDX: Genetic Testing for Heritable Thoracic Aortic Disease

Billing and Coding: MolDX: Genetic Testing in Heritable Thoracic Aortic Disease		 08/29/24 10/12/24 C      
MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy

Billing and Coding: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy		 08/31/23 10/14/23 F View 08/08/24 View
MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis		 08/29/24 10/12/24 C      
MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

Billing and Coding: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma		 06/08/23 07/22/23 F View 07/04/24 View
MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules

Billing and Coding: MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules		 08/31/23 10/14/23 F View 08/29/24 View
MolDX: Molecular Testing for Solid Organ Allograft Rejection

Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection		 08/10/23 09/23/23 E  
MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

Billing and Coding: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms		 08/01/24 09/15/24 C  
Last Updated Dec 11 , 2024